Pfizer to buy Global Blood for over $5B

By Associated Press

Aug 09, 2022 12:03 am

PFIZER INC. will spend about $5.4 billion to purchase Global Blood Therapeutics (GBT) as the pharmaceutical giant continues to invest some of the cash influx reaped during the Covid-19 pandemic.

The company said on Monday the acquisition would boost its capabilities in rare hematology. Global Blood makes Oxybryta tablets for treating sickle cell disease. Its sales reached about $195 million last year.

This May 4, 2014 file photo shows Pfizer’s logo on a former factory in Brooklyn, New York City. AP PHOTO

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Japan's SoftBank plans to invest $100B in US

Oil prices nudge down

Japan targets 40-50% renewables by 2040

Singapore's Nov exports rise 3.4%

Cocoa prices hit fresh 7-1/2-month peak

Malaysia launches first locally made EV

ChatGPT search opens to all users